A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population

Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study

(2015) Cem Gabay et al.   ANNALS OF THE RHEUMATIC DISEASES

Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry

(2015) Ziga Rotar et al.   CLINICAL RHEUMATOLOGY

Adherence to Anti–Tumor Necrosis Factor Therapy Administered Subcutaneously and Associated Factors in Patients With Rheumatoid Arthritis

(2015) Fausto Salaffi et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice

(2014) C. Fortunet et al.   RHEUMATOLOGY

EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases

(2013) N Duru et al.   ANNALS OF THE RHEUMATIC DISEASES

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab

(2013) M Neovius et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis

(2013) Y Hishitani et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry

(2012) Jeffrey D Greenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study

(2012) Michael E. Weinblatt et al.   ARTHRITIS AND RHEUMATISM

Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry

(2011) H. C. Leffers et al.   ANNALS OF THE RHEUMATIC DISEASES

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

(2011) M. M. Soliman et al.   ANNALS OF THE RHEUMATIC DISEASES

Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

(2010) S. L. Gorter et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-tumour necrosis factor   therapy in patients with rheumatoid arthritis results in a significant and long-lasting decrease of concomitant glucocorticoid treatment

(2009) L Naumann et al.   ANNALS OF THE RHEUMATIC DISEASES

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

(2009) Merete Lund Hetland et al.   ARTHRITIS AND RHEUMATISM

Initiation of rheumatoid arthritis treatments and the risk of serious infections

(2009) Carlos G. Grijalva et al.   RHEUMATOLOGY

Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis

(2008) J N Hoes et al.   ANNALS OF THE RHEUMATIC DISEASES